- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00714584
Pharmacokinetics of Naltrexone Following Intravenous and Oral Routes of Administration in Healthy Volunteers
Pharmacokinetics of Naltrexone Hydrochloride (HCl) Following Intravenous (i.v.) and Oral Routes of Administration in Healthy Subjects
Study Overview
Detailed Description
Naltrexone blocks the effects of opioid (morphine-like) drugs by competitive binding at the opioid receptors in the brain. Naltrexone does not possess morphine-like properties and exhibits minimal pharmacologic activity. Naltrexone is marketed as an oral tablet. A wide range of oral bioavailability values have been reported for naltrexone. The wide range in oral bioavailability of naltrexone appears to be due to differences in assay specificity and the method of estimation of bioavailability (use of total drug, free drug, or urinary excretion data rather than plasma level). This was a single-center, randomized (study drug assigned by chance), open-label, 2-treatment, 2-period crossover study in healthy volunteers. Healthy volunteers were randomly assigned to 1 of 2 treatment sequences (AB or BA) with a washout period of 6 to 14 days between treatments. The washout period commenced the day of dosing, after drug administration. Blood samples for determination of blood naltrexone levels were collected at scheduled time points from the arm opposite to the 1 selected for naltrexone i.v. administration. Pulse, blood pressure, breathing rate, body temperature were measured at the times listed in the study schema. Healthy volunteers remained at the research facility for blood sample collection periods and were monitored for adverse events throughout the treatment periods.
Treatment A: 1 mg naltrexone HCl administered i.v. over 15 minutes (naltrexone i.v.). Treatment B: 50 mg naltrexone HCl administered orally (naltrexone oral).
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy, non smoker, men and nonpregnant nonlactating women
- Weighing a minimum of 60 kg and were within 15% of ideal weight for height as described in the Metropolitan Life Insurance Height and Weight Standards
- Who did not have a history or show presence of drug or alcohol dependence or abuse
Exclusion Criteria:
- Known allergy or hypersensitivity to naltrexone
- Usage of prescription medication including opioids (except for birth control medications, sex-hormone replacement, vitamins) within 14 days prior to Day 1, over-the-counter medication (except for vitamin supplements or acetaminophen [less than 2 g/day]) or herbal medication within 3 days prior to Day 1, alcohol, grapefruit juice, or caffeine within 48 hours before dosing
- Consumption of more than 450 mg of caffeine per day (eg, approximately 5 cups of tea, 3 cups of regular coffee, or 8 cans of cola)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Evaluate the pharmacokinetics of naltrexone following i.v. and oral routes of administration in healthy volunteers, and to assess the absolute bioavailability of naltrexone following oral administration.
|
Secondary Outcome Measures
Outcome Measure |
---|
Assessment of safety. Vital signs, Physical examination, clinical laboratory tests, and electrocardiogram were performed at screening and study termination. Additionally, vital signs were recorded on Days 1 and 2 of both treatment periods.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR003256
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Biological Availability
-
Fundació EurecatCirce, S.L.Not yet recruiting
-
DaacroISTITUTO KURZ ITALIA S.R.L.; Institut Kurz GmbH; Fattoria La Vialla di Gianni...CompletedBiological AvailabilityGermany
-
Wageningen UniversityCompletedBiological Availability
-
Janssen Infectious Diseases BVBACompletedHealthy | Biological AvailabilityNetherlands
-
Fundació EurecatSilicium Laboratories S.L.; San Antonio Technologies S.L.; Catholic University... and other collaboratorsCompletedBiological Availability | Aluminium OverloadSpain
-
PfizerCompletedBiological AvailabilityUnited States
-
Xspray Pharma ABQPS Bioserve India Pvt LimitedCompleted
-
University of HohenheimUniversidad de Costa RicaCompletedBiological AvailabilityCosta Rica, Germany
-
BayerOrion Corporation, Orion PharmaCompletedBiological AvailabilityGermany
-
Pronova BioPharmaCompletedBiological AvailabilityUnited Kingdom
Clinical Trials on Naltrexone HCl.
-
University of Alabama at BirminghamWithdrawn
-
PfizerCompletedLow Back Pain | Chronic Pain | AnalgesiaUnited States
-
TakedaWithdrawnWeight Regain Post Bariatric SurgeryUnited States
-
PfizerCompleted
-
USWM, LLC (dba US WorldMeds)National Institute on Drug Abuse (NIDA)Completed
-
Boston Children's HospitalCompletedNew Daily Persistent Headache (NDPH)United States
-
Weill Medical College of Cornell UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)TerminatedProlonged Grief DisorderUnited States
-
Milton S. Hershey Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); The...CompletedInflammation | Crohn's DiseaseUnited States
-
Xhale AssuranceNational Institute on Drug Abuse (NIDA)Completed
-
Massachusetts General HospitalUnited States Department of DefenseCompletedADHD | Stimulant-Induced EuphoriaUnited States